Legacy
Research Projects
This section offers an overview of the research questions that were approved for execution during the HARMONY and HARMONY PLUS projects inside the HARMONY Platform. Each project offers an overview of the objectives of the research question, the core team of researchers involved, and the results obtained during the duration of the funding period.
ALL 1: Use of Big Data to improve outcomes for patients with Acute Lymphoblastic Leukemia
- ALL, HARMONY, Leukemia
ALL-2: Prognostic value of IKZF1 Gene Alterations in Adult BCP-ALL
- AML, HARMONY, Leukemia
ALL-3: Exploring treatment patterns and outcomes in older adult B-ALL
- ALL, HARMONY, Leukemia
ALL-4: Harnessing the Power of Big Data to Predict Outcomes Post-Stem Cell Transplant in Adult R/R ALL
- ALL, HARMONY, Leukemia
ALL-5: Exploring the prognostic significance of minimal residual disease (MRD) in children with ALL
AML-1: Use of Big Data to revise treatment strategies in Acute Myeloid Leukemia
- AML, HARMONY, Leukemia
AML-2: Optimizing Acute Promyelocytic Leukemia Management Using Big Data
- AML
AML-3: Using big data to shed light on the clinical impact of genomic alterations in sAML/tAML
- AML, HARMONY, Leukemia
AML-4: Using big data to confirm the link between MRD and survival in AML
- AML, HARMONY, Leukemia
AML-5: Exploring a role for HARMONY data as historical control in elderly Acute Myeloid Leukemia patients.
- AML, HARMONY, Leukemia
AML-6: Unravelling the Clinical Impact of Co-mutations in NPM1mut AML
- AML, HARMONY, Leukemia
AML-7: The impact of gender on genetic aberrations and clinical outcomes in AML
- AML, HARMONY, Leukemia
AML-8: Clinical Meaning and Prognostic Implications of Non-Canonical Non-Type A NPM1 Mutations in Acute Myeloid Leukemia
- AML, HARMONY, Leukemia
CLL-1: Harnessing big data to predict prognosis in Chronic Lymphocytic Leukemia
- CLL, HARMONY, Leukemia
CLL-2: Exploring the occurrence of other malignancies in CLL patients using the HARMONY BigData platform
- CLL, HARMONY
CML-1: Understanding the clonal hierarchy in Chronic Myeloid Leukemia to help improve patient outcomes
- CML, HARMONY PLUS, Leukemia
CML-2: Using Big Data to Map and Identify Optimal Treatment Pathways to Treatment-Free Remission in CML
- CML, HARMONY PLUS, Research
CML-3: A comparison study of “toxicity over time” and QoL among all available TKI options
- CML, HARMONY PLUS, Leukemia
CML-4: Correlation of demographic, disease and therapy factors with toxicity and tolerability of the different TKIs
- CML, HARMONY PLUS, Leukemia
CML-5: Prevalence of clinically relevant problems and symptoms in patients with CML
- CML, HARMONY PLUS, Leukemia
MDS-1: Prognostic factors to hypomethylating agents and intensive chemotherapy in higher risk Myelodysplastic Syndromes
- HARMONY, Leukemia, MDS
MDS-2: A retrospective study of patients with Myelodysplastic Syndrome
- HARMONY, Leukemia, MDS
MDS-3: Differential outcomes of patients with MDS undergoing HSCT vs non-transplant strategies
- HARMONY, Leukemia, MDS
MDS-4 Impact of pre-transplant cytoreductive treatment on high-risk MDS patients undergoing allo-HSCT
- HARMONY, Leukemia
MM-1: Optimizing prognostication and personalizing treatment in Multiple Myeloma
- HARMONY, MM, Myeloma
MM-2: Contextualizing clinical trials by developing robust historical control arm cohort
- HARMONY, MM, Myeloma
MPN-1: Exploring the Impact of Covid-19 on Outcomes in Myeloproliferative Neoplasms
